Pentadeca arginate: a new name with almost no published literature behind it
A compound that arrived in the peptide market recently, described as a more stable version of BPC-157. Almost everything written about it is inference from BPC-157 or claims from people selling it, and the difference between those two categories and published evidence is what this page is for.
Regulatory status. Research compound — no FDA approval. Not for human use label in most jurisdictions. That is the app’s own field, reproduced here rather than summarised. It means no regulator has reviewed a manufacturer’s evidence for identity, purity, potency or safety in people for this compound, so nothing below is a marketing claim about a product you can buy.
Purity, identity and concentration are therefore unverified by anyone but whoever made the vial. The storage rule in the fact box below is general practice for this formulation rather than a specification for a particular product: General handling practice for this formulation. Your supplier’s own insert or COA overrides anything here.
This page names no vendor, no clinic and no testing service, and there is no discount code anywhere on this site — the moment a page like this recommends where to buy, it stops being information.
- Also known as
- PDA, PC-15
- Class
- Peptide
- Regulatory status
- Research compound — no FDA approval. Not for human use label in most jurisdictions.
- Before mixing
- Sealed powder tolerates room temperature in transit, but keep it refrigerated at 2–8 °C (36–46 °F) for anything beyond a few weeks, or frozen for months. Keep it dark — the carton it shipped in is doing a job.
- After mixing
- Once reconstituted with bacteriostatic water: refrigerate at 2–8 °C and use within about 28 days. The benzyl alcohol in bacteriostatic water is what buys that window — plain sterile water has no preservative, so a vial mixed with it should be treated as one sitting only. Kits are usually ten vials: only the one you mixed is on that 28-day clock — the sealed ones keep their own, much longer shelf life, so store them as powder, not as solution.
- What ruins it
- Do not freeze a reconstituted vial. Repeated freeze–thaw is one of the more reliable ways to degrade a peptide.
- Handling caveat
- General handling practice for this formulation. Your supplier’s own insert or COA overrides anything here.
What it is said to be
Pentadeca arginate is presented as the same fifteen-amino-acid sequence as BPC-157 prepared as an arginate salt rather than the acetate form, with the claim that the salt form improves stability and shelf life. Animal-only or theoretical Salt form genuinely does affect the stability and solubility of a peptide, so the claim is chemically plausible on its face. Plausible is where it stops.
The app's entry describes enhanced tissue regeneration and nitric-oxide pathway activity relative to BPC-157. Those are the claims that circulate; they are not conclusions from a published comparison, because no published comparison exists. The app's own drawbacks list says this in its first two items, and it is right to.
The honest statement of the evidence is short. There is no peer-reviewed pharmacology, no published pharmacokinetics — the app holds no half-life or time to peak, which is why the fact box above carries no pharmacokinetic rows — no animal literature under this name, and no human data. Everything favourable said about it is either transferred from BPC-157's animal literature or originates with a seller.
Why transferring BPC-157’s evidence does not work
BPC-157's evidence base is itself entirely animal work with no human controlled trials, so the strongest possible inference here is from an already-limited body of research to a preparation that has not been studied. That is two steps removed from a human finding, and each step is doing real work.
A changed salt form is a change to the preparation, and it is offered as the reason for claimed superiority — so the same argument that makes PDA worth a different name is the argument against assuming BPC-157's results apply to it. Either it behaves differently, in which case the borrowed evidence does not transfer, or it behaves the same, in which case there is no reason to prefer it. Both cannot be true at once.
Animal-only or theoretical The identity problem is more acute here than for most research compounds. With no reference standard, no published analytical method under this name and no approved product, a vial labelled pentadeca arginate cannot be checked against anything. This site names no vendor and no testing service, and for this compound in particular a page that recommended a source would be worthless as well as inappropriate.
What a reasonable position looks like
None of this makes the compound harmful. It makes it unstudied, which is a different claim and a more accurate one. A short peptide from a sequence with a large animal literature is not an outlandish thing to be interested in, and a stability improvement would be a genuine practical benefit if it were demonstrated.
What is not reasonable is the confidence with which it is usually described. The specific claims — superior regeneration, enhanced nitric-oxide signalling, better bioavailability — are precisely the claims that would require the studies nobody has published, and repeating them without that caveat is how a marketing position becomes a widely believed fact.
Anyone using this or considering it should say plainly to their clinician what it is: an unstudied preparation of a sequence whose own evidence is animal-only. That is the conversation that lets someone weigh it properly, and anything that feels wrong while using it is a reason to stop and ask rather than to continue.
The dosing rows the app records
Off-label or community practice Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.
| Label | Amount | Route and frequency | Duration recorded |
|---|---|---|---|
| Starting | 250mcg/day | SubQ once daily near target tissue | 4-6 weeks |
| Therapeutic | 500mcg/day | SubQ twice daily | 6-12 weeks |
What the app monitors alongside it
The panel below is the app’s own monitoring note for Pentadeca Arginate, verbatim. None of the analytes it names has a page here yet.
- Monitoring panel
- No specific labs. Monitor injection sites. Liver enzymes if extended use.
Drawbacks and risks the app records
From the app's own entry, and it is the most useful drawbacks list in this reference precisely because every item is about the state of the evidence rather than a symptom.
- Even more limited human data than BPC-157
- Very new compound — long-term safety completely unknown
- Difficult to source with verified purity
- Higher cost than BPC-157
- Mechanism not fully characterized
- Research still in early stages
Questions people actually ask
Is PDA better than BPC-157?
No published comparison exists, so the honest answer is that nobody knows. The claim is made by people selling it, and it rests on a stability argument that is chemically plausible and has not been demonstrated for this preparation.
Why is there no half-life in the fact box?
Because the app holds none, and it holds none because no pharmacokinetic characterisation has been published under this name. Any duration or clearance figure quoted elsewhere is borrowed from BPC-157 or invented.
Is it the same molecule as BPC-157?
It is described as the same peptide sequence in a different salt form. If that is accurate, it is the same molecule in solution with different handling properties. Whether a given vial contains what the label says is unverifiable outside a laboratory, and there is no reference standard to verify it against.
Should the BPC-157 page be read alongside this one?
Yes — the BPC-157 page covers the animal literature this compound's reputation is borrowed from, including what that literature does and does not support. It is the more informative of the two pages, because there is more to say.
Where the load-bearing numbers come from
Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.
- Absence of published literature under this name
- No peer-reviewed pharmacology, pharmacokinetics, animal study or human data has been published for pentadeca arginate as of this review date
- BPC-157’s own evidence base
- A rodent literature with no published human controlled trials; see the BPC-157 page on this site
- Salt form and peptide stability
- General peptide chemistry; the principle is established, its application to this preparation is not demonstrated
- Absence of pharmacokinetic data
- app.html holds no half-life or time-to-peak entry for this compound, which is why no such rows appear above
When there is no published dose and no published half-life, your own record is the entire dataset. TherapyLog keeps the amount, the date and what followed.
Save this dose to your log